retatrutide nonalcoholic steatohepatitis trial Results: 28.3% Weight Loss Data Retatrutide significantly improved liver health

When starting semaglutide, begin with lower doses (0.51 mg) to assess tolerance alongside any early semaglutide adjustment symptoms

GLP-1 receptor agonist use does not increase risk of respiratory complications post-endoscopy

Dermatologic outcomes: GLP-1 RA versus DPP-4i use The mean follow-up duration was 1,080 454 days in the GLP-1 RA group and 1,121 498 days in the DPP-4i group ( Supplementary Figure 1 )

It enhances GLP-1 production and researchers suggests that the medicinal herb may serve as a therapeutic agent for diabetic mellitus

Tirzepatide has been compared with placebo, subcutaneous semaglutide, insulin degludec, insulin glargine and insulin lispro

The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by d-amphetamine and augments lithium effects in mice: relevance for bipolar disorder